IsoTherapeutics Group, LLC was founded in 2005 by two entrepreneur scientists with a passion for advancing the technology of radiopharmaceuticals.
IsoTherapeutics Group prides itself on collaborating with key companies, universities, and medical centers that complement our offerings and technologies for developing novel diagnostic and therapeutic agents for severe diseases. Current collaborators include MI Bioresearch, PerkinElmer, MD Anderson Cancer Center, University of Missouri – Columbia, RadioMedix, Excel Diagnostics, Texas A&M University, Valco Instruments Company and several other virtual or near-virtual biopharma companies.
The company scientists have extensive experience in the development of radiopharmaceuticals, particularly bone-seeking radiopharmaceuticals. Additionally, we have experience designing antibody conjugates for radioimmunotherapy. Our capabilities include synthetic organic chemistry and chelation chemistry, with particular expertise in bifunctional chelants for radiolabeling proteins. Additional capabilities include radioanalytical and radiochemistry, with expertise in diagnostic and therapeutic isotopes. The company has a radioactive materials license to handle radioisotopes of interest to the radiopharmaceutical community. ITG has a small animal testing facility to perform biodistribution and pharmacokinetic studies on normal and/or xenograft models using radio¬labeled compounds.
The company scientists, while employed at the Dow Chemical Company developed QUADRAMET® a radiopharmaceutical for treatment of bone pain due to metastatic cancer, treatments for arthritis, osteoporosis, and osteomyelitis, just to name a few. IsoTherapeutics Group scientists have received over 100 patents for developing chemistry and radiopharmaceutical formulations.
IsoTherapeutics Group works with customers in a variety of ways. We engage with customers every step of the way with the final goal being reduction of costs and shortening of the time to clinical trials.